A comprehensive evaluation of apixaban in the treatment of venous thromboembolism

  title={A comprehensive evaluation of apixaban in the treatment of venous thromboembolism},
  author={Jennifer Koehl and Bryan D Hayes and Hanny Al‐Samkari and Rachel P. Rosovsky},
  journal={Expert Review of Hematology},
  pages={155 - 173}
ABSTRACT Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more convenient and accessible alternatives to warfarin or parenteral agents for the treatment of venous thromboembolism (VTE). Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is approved for the acute treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) as well as for the reduction in the risk of recurrent DVT and PE following initial therapy. Areas covered: This… 
6 Citations
Anticoagulation in COVID-19: current concepts and controversies
This article seeks to review the present guidelines and recommendations as well as the ongoing trials on use of anticoagulants in COVID-19, identify discrepancies between all these, and provide a comprehensive strategy regarding usage of these drugs in the current pandemic.
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery.
Detailed structure-activity relationship studies using a C-ring-truncated version of Vorapaxar culminated in the discovery of three leads, represented as 13, 14, and 23, which possessed favorable pharmacokinetic properties and an off-target profile.
Differential Approach to Surgical and Endovascular Treatments of Pulmonary Thromboembolism in Patients with Neurological and Neurosurgical Problems
Surgical treatment of PE is effective and safe with predictable results and endovascular catheter induced destruction of the thromboembolus substrate is an alternative to the surgical treatment of patients with a high-risk of open surgery and absolute contraindications forThrombolytic therapy.
Currently available drugs for the treatment of Coronavirus-2
  • T. Anbarasan, Gaurav Sahu, A. Goyal
  • Medicine, Biology
    Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection
  • 2022
Aktuelle Aspekte und Strategien zum Einsatz oraler Antikoagulantien und Plättchenfunktionshemmer in der Praxis
Aufgrund erhöhter venöser und arterieller Risiken und Begleiterkrankungen bei entzündlich-rheumatischen Erkrankungen sind die Grundprinzipien der adäquaten medikamentösen Behandlung auch von


Management of Venous Thromboembolism
Clinical data on direct oral anticoagulants used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products are reviewed as a paradigm shift from oral VKAs are reviewed.
New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
NoACs are as efficient in the treatment of VTE as VKA but with reduced risk of bleeding complications, and indirect comparisons indicate differences in the risk of clinically relevant bleeding events.
Oral apixaban for the treatment of acute venous thromboembolism.
A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.
Direct oral anticoagulants in hypercoagulable states
Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability is uncertain.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
The attractive fixed‐dose regimen of this compound may meet the demand to simplify anticoagulant treatment in patients with established venous thromboembolism and warrant further evaluation of apixaban in phase III studies.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
DOAs seem to be as effective and safe as conventional treatment for the prevention of VTE in patients with cancer.
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
The main objective of this study is to present recent data on non-vitamin K antagonist oral anticoagulants (NOACs) and to analyze their advantages and disadvantages compared with those of VKAs based on a large number of recent studies.
Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management
Results for safety outcomes according to ‘real world evidence’ (RWE) are in-keeping with randomised controlled trials (RCTs) and currently, all 4 DOACs have been deemed at least as effective as warfarin, while demonstrating superiority in some aspects.